Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $287.50 short put and a strike $282.50 long put offers a potential 16.28% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $287.50 by expiration. The full premium credit of $0.70 would be kept by the premium seller. The risk of $4.30 would be incurred if the stock dropped below the $282.50 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 42.7 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up
Thu, 05 May 2022 15:12:03 +0000
United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
12 Best American Stocks To Buy in 2022
Wed, 04 May 2022 13:23:14 +0000
In this article, we discuss the 12 best American stocks to buy in 2022. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best American Stocks To Buy in 2022. The beginning of 2022 brought along something investors hadn’t witnessed since the early days of 2020: […]
Lilly to Participate in Bank of America Securities 2022 Healthcare Conference
Tue, 03 May 2022 18:00:00 +0000
Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Securities 2022 Healthcare Conference, May 10-11, 2022. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat on Tuesday, May 10 at 7:40 p.m., Eastern time.
Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates
Tue, 03 May 2022 15:53:03 +0000
Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.
Tesla, Lilly, Microsoft Fight Sell-Off As Indexes Search For Bottom
Mon, 02 May 2022 19:58:26 +0000
With the market searching for a bottom, Tesla, Microsoft, Eli Lilly and other leading stocks try to recharge as May kicks off.
Also on Market Tamer…
Follow Us on Facebook